Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Primary Myelofibrosis Market From 2025 to 2029?

The market size for primary myelofibrosis has experienced significant growth in the past few years. Estimates predict the market size will increase from $0.79 billion in 2024 to $0.84 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.4%. This growth during the historical period is ascribed to factors such as enhanced disease recognition among healthcare professionals, an increasing utilization of jak inhibitors, improved diagnostic techniques and genetic testing capacities, heightened patient access to hematological experts, and an upswing in clinical trial activities.

The market for primary myelofibrosis is set to experience robust growth in the ensuing years, propelling to a value of $1.07 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. Factors leading to this expansion throughout the forecast period include the burgeoning pipeline of innovative therapies, the heightened need for treatments that alter disease progression, increasing occurrence among the elderly, a growing focus on combination therapies, and more investment from pharmaceutical and biotech companies. Key trends predicting these market changes encompass the rise in target-specific drug advancements, the use of next-generation sequencing (ngs) in diagnostic practices, the emergence of technology-based monitoring options, the evolution of combination therapy procedures, and improvements in imaging techniques for bone marrow fibrosis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Elements Are Contributing To Growth In The Primary Myelofibrosis Market?

The anticipated rise in myelofibrosis cases is set to trigger expansion in the primary myelofibrosis market. Myelofibrosis, a unique bone marrow cancer type, interrupts the typical blood cell production process in the body, causes extensive bone marrow scarring, and leads to severe anemia, weakness, fatigue, and spleen enlargement. A primary factor in the growing prevalence of myelofibrosis is the aging demographic, given that individuals over 60 are most likely to develop the disease, and increased life expectancy has led to a surge in diagnosed cases. This increase in myelofibrosis cases drives improvements in managing primary myelofibrosis by encouraging research, supporting early detection, expanding treatment choices, and fostering enhanced clinical guidelines and specialist care. For example, a November 2024 report from the UK’s independent executive non-departmental public body, the National Institute for Health and Care Excellence, revealed a myelofibrosis prevalence rate of 3.2 per 100,000 individuals in the UK and an incidence rate of 0.6 per 100,000. Consequently, the escalating prevalence of myelofibrosis fuels the expansion of the primary myelofibrosis market.

Which Segments Are Detailed In The Global Primary Myelofibrosis Market Report?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Emerging Trends And Strategic Shifts Are Shaping The Primary Myelofibrosis Market?

Key players in the primary myelofibrosis market are centering their efforts on creating groundbreaking products like Janus kinase 2 inhibiting tablets in order to enhance symptom management and slow the progression of the disease. These oral medications, which hinder the activity of the JAK2 enzyme, play a significant role in halting the aberrant signaling pathways that lead to an excess production of blood cells in primary myelofibrosis. This helps in minimizing the size of the spleen, relieving fatigue and bone pain, and decelerating disease progression. For instance, in March 2025, a significant development was witnessed when GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotech firm based in Korea, rolled out Omjjara (momelotinib), a fresh treatment option for myelofibrosis. Approved by South Korea’s Ministry of Food and Drug Safety, the treatment is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who are also suffering from moderate to severe anemia. Omjjara is a JAK1 and JAK2 inhibitor and also inhibits activin A receptor type 1 (ACVR1), efficiently treating symptoms like anemia, increased spleen size, and fatigue. The endorsement of the treatment is backed by clinical trial data that indicates significant improvements in symptoms compared to traditional treatments.

Who Are The Key Contributors To Growth In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Is Projected To Lead The Primary Myelofibrosis Market By 2025?

North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model